Experimental drugs for brain cancer show promise

05/23/2008 | NYTimes.com

Cancer experts hope several promising drugs will follow the success of Genentech's Avastin and Schering-Plough Corp.'s Temodar and reduce brain cancer deaths. An experimental vaccine bought by Pfizer from Avant Immunotherapeutics allowed early clinical trial patients to live twice longer than expected. A vaccine candidate in Northwest Biotherapeutics' pipeline also extended survival to at least three years among some of the patients in an early trial.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL